Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The discontinuation of danuglipron was a significant strategic setback, leaving Pfizer without a GLP-1 programme in the world's fastest-growing peptide market
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System, Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I, Pharmaceuticals (Basel), Pharmaceuticals, 2025 Jun 19;18(6):928
& Villen, J
Dihexa should be considered a research-stage compound with entirely unknown human safety profile
The table above provides the reconstitution math
Key adverse effects include sexual dysfunction and, rarely, mood changes
US$ 22.07
US$ 29.03
US$ 24.35
US$ 25.43
US$ 23.20
US$ 23.56
US$ 21.99
US$ 22.93
